University of Zambia, School of Medicine
Welcome,         Profile    Billing    Logout  
 2 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
KHOSA, Celso
panTB-HM, NCT05686356: A Pan-TB Regimen Targeting Host and Microbe

Recruiting
2/3
352
RoW
Sutezolid, N-acetyl cysteine, NAC, Pretomanid, Bedaquiline, Rifafour
The Aurum Institute NPC, Ludwig-Maximilians - University of Munich, Stichting Katholieke Universiteit, Wits Health Consortium (Pty) Ltd, Instituto Nacional de Saúde, Mozambique, National Institute for Medical Research, Tanzania, University of Stellenbosch, Sequella, Inc., Global Alliance for TB Drug Development
Tuberculosis
09/25
09/25
Archary, Moherndran
NCT03016533: Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

Completed
3
101
US, RoW
Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets, ABC/DTG/3TC film-coated dispersible tablets
ViiV Healthcare
HIV Infections
12/24
12/24
LATA, NCT05154747: Long-Acting Treatment in Adolescents

Active, not recruiting
3
476
RoW
Cabotegravir, Rilpivirine Drug Combination, CAB, RPV, TLD
University College, London, European and Developing Countries Clinical Trials Partnership (EDCTP), Janssen-Cilag Ltd., ViiV Healthcare, Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands., London School of Hygiene and Tropical Medicine, MRC/UVRI and LSHTM Uganda Research Unit, Africa Health Research Institute, PENTA Foundation, University of York
Hiv, HIV Infections, HIV-1-infection, Paediatric Human Immunodeficiency Virus Infection
03/25
03/26
COMET-PACE, NCT05124210 / 2021-003717-18: Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

Terminated
2
8
US
Sotrovimab
GlaxoSmithKline, Vir Biotechnology, Inc.
COVID-19
06/23
06/23
NCT04648280: Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their CART and Have Dual- or Triple-class Antiretroviral Resistance

Recruiting
1/2
60
US, RoW
Fostemsavir
PENTA Foundation, ViiV Healthcare, PHPT Foundation, Hospital Universitario 12 de Octubre, Cromsource
HIV Infections with Multi Drug Resistant Virus
06/25
06/28

Download Options